Results 151 to 160 of about 78,778 (305)

Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights

open access: yesBritish Journal of Pharmacology, EarlyView.
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra   +5 more
wiley   +1 more source

Machine Learning‐Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma

open access: yesCancer Science, EarlyView.
An immune‐related 12‐gene signature developed through integrative machine learning stratified overall survival across multiple myeloma cohorts and remained independently associated with outcome. Single‐cell, somatic mutation, and transcriptome‐based drug‐response analyses further linked the signature to multicellular bone marrow context, distinct ...
Kai Wang   +10 more
wiley   +1 more source

Treatment‐Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure

open access: yesCancer Science, EarlyView.
Immune surveillance of residual leukemic stem cells after tyrosine kinase inhibitor discontinuation involves coordinated NK‐cell, CTL, Treg, pDC, and neutrophil activity that predicts treatment‐free remission, while exhausted CTLs and Treg expansion predict relapse in chronic myeloid leukemia.
Hiroshi Ureshino, Shinya Kimura
wiley   +1 more source

Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH‐MM‐15 Study

open access: yesCancer Science, EarlyView.
t(11;14)‐positive MM is a clinically distinct subgroup characterized by intermediate prognostic risk, modest response depth, and treatment‐dependent outcomes. ABSTRACT t(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor.
Taku Tsukamoto   +24 more
wiley   +1 more source

CD38 and its role in oxytocin secretion and social behavior [PDF]

open access: yes
Here, we review the functional roles of cyclic ADP-ribose and CD38, a transmembrane protein with ADP-ribosyl cyclase activity, in mouse social behavior via the regulation of oxytocin (OXT) release, an essential component of social cognition.
111   +11 more
core   +1 more source

Antibody M-19 distinguishes intracellular and extracellular CD38

open access: yes, 2013
CD38 is an enzyme capable of synthesizing two second messengers, cyclic ADP ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP). Generally, CD38 is considered as a Type II membrane protein, which means the catalytic active domain ...
Wang, X, Zhao, Y, Lee, HC
core  

Macrophage Lipid Homeostasis Drives IVDD via a Senescence‐Dependent Impairment of Efferocytosis

open access: yesCell Proliferation, EarlyView.
Intervertebral disc degeneration (IVDD) has been a leading cause of low back pain and lacks disease‐modifying therapies. Although dysregulated disc lipid metabolism is implicated, its impact on the immune microenvironment, particularly macrophages, remains unknown.
Jinyu Wang   +12 more
wiley   +1 more source

Cytology‐First Diagnostic Workflow for Melanoma of Unknown Primary With Molecular Profiling

open access: yesCytopathology, EarlyView.
Cytology‑first diagnostic workflow for melanoma of unknown primary. Fine‑needle aspiration of an enlarged lymph node enables rapid cytologic evaluation and immunocytochemical confirmation of melanocytic lineage (SOX10). This early cytologic diagnosis facilitates timely surgical excision and comprehensive genomic profiling, supporting integrated ...
Hong Yu   +3 more
wiley   +1 more source

Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany—A Multi‐Center Analysis

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase‐III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined.
Maria Dampmann   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy